Currentblue cross blue shield - south dakotaPolicy 06.01.38

Lutathera (Lutetium Lu 177 Dotatate)

Defines medical necessity, prior authorization, dosing regimen, and eligibility criteria for Lutathera in patients with neuroendocrine tumors and select related indications for Blue Cross Blue Shield - South Dakota members.

Policy Summary

Payerblue cross blue shield - south dakota

PolicyLutathera (Lutetium Lu 177 Dotatate)

Policy CodePolicy 06.01.38

Change TypeNo material change

Effective DateMay 1, 2018

Next Review Date

Key ActionObtain prior authorization and document SSTR-positive imaging, pathology (including Ki-67), and planned FDA-consistent dosing of 7.4 GBq (200 mCi) every 8 weeks for up to 4 doses.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Prior approval requiredauthorization requirement

4FDA-approved total doses

>=12minimum age

≤20%Ki-67 threshold

>=3x ULNbilirubinemia discontinuation

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

CrCl discontinuation

Coverage Criteria for Lutathera (Lutetium Lu 177 Dotatate)

Medically Necessary Indications

Lutetium 177 (Lu 177) dotatate is considered medically necessary in patients 12 years and older when ONE of the following indications is met AND all additional requirements are satisfied:

Choose one of the following indications: 1) Distant metastases of bronchopulmonary or thymus neuroendocrine tumors with clinically significant tumor burden AND (a) low grade (typical) <2 mitoses/10 HPF and no necrosis OR evidence of progression OR (b) intermediate (atypical) 2–10 mitoses/10 HPF and/or foci of necrosis; and Lutathera will be given as primary therapy;age >= 12 years

Indication 1 per policy

Choose one of the following indications: 2) Gastroenteropancreatic neuroendocrine tumors (GEP‑NETs; foregut, midgut, hindgut) that are unresectable, locally advanced, or metastatic AND disease progression despite somatostatin analog therapy (e.g., octreotide or lanreotide) or molecularly targeted therapy (e.g., everolimus) AND pathology documents well‑differentiated tumor with Ki‑67 ≤ 20%;age >= 12 years

Indication 2 per policy

Choose one of the following indications: 3) Locally unresectable bronchopulmonary or thymus neuroendocrine tumors that are low grade (<2 mitoses/10 HPF) with no necrosis AND Lutathera will be used as subsequent therapy after progression on first‑line therapy (octreotide or lanreotide);age >= 12 years

Indication 3 per policy

Choose one of the following indications: 4) Locally unresectable or metastatic pheochromocytoma or paraganglioma AND no prior treatment with a radiolabeled somatostatin analog;age >= 12 years

Indication 4 per policy

Choose one of the following indications: 5) Poorly controlled carcinoid syndrome related to a neuroendocrine tumor AND symptom progression on octreotide LAR OR lanreotide OR telotristat;age >= 12 years

Indication 5 per policy

General requirements (apply to all indications): Documented target lesions over‑expressing somatostatin receptors confirmed by an appropriate somatostatin receptor‑based imaging study (lesion uptake > liver); AND adequate bone marrow, renal, and hepatic function as determined by the treating physician.SSTR uptake > liver

See policy guidelines for acceptable imaging modalities

Investigational / Not Medically Necessary

Investigational / Not Medically Necessary: Greater than a total of 4 doses as per the FDA‑approved regimen; pediatric individuals 17 years or less; when the above medically necessary criteria have not been met; and for all other indications not listed above.

These uses are considered investigational due to insufficient evidence.

Initial Therapy — Lutetium 177 dotatate for GEP-NETs

Covered when ALL of the following are met

Indication and disease state: Individual has inoperable locally advanced or metastatic somatostatin receptor‑positive gastroenteropancreatic neuroendocrine tumor (GEP‑NET; foregut, midgut, or hindgut)

Treatment history: Disease has progressed on first‑line somatostatin analogue therapy (e.g., octreotide or lanreotide) or molecularly targeted therapy when specified

Consistent with study selection and FDA‑labeling

Provider qualification: Therapy is administered by or under physicians qualified in radiopharmaceutical use as approved by the appropriate governmental agency

Per regulatory and policy requirements

Initial Therapy

Covered when ALL of the following are met:

Initial coverage criteria: 1) Individual has inoperable locally advanced or metastatic gastroenteropancreatic neuroendocrine tumor (GEP‑NET); 2) Tumor is somatostatin receptor–positive on imaging (e.g., octreoscan uptake ≥ normal liver); 3) Disease has progressed on first‑line somatostatin analog therapy; 4) Performance status and organ function consistent with trial inclusion (e.g., Karnofsky ≥60 and creatinine clearance thresholds per clinical judgment/trial: NETTER‑1 included CrCl ≥50 mL/min; NETTER‑2 excluded CrCl <40 mL/min); 5) Treatment plan consistent with trial/FDA dosing (Lu 177 dotatate 7.4 GBq [200 mCi] every ~8 weeks for up to 4 doses) and monitoring for expected toxicities.

Derived from trial inclusion criteria and FDA regimen.

Coverage considerations by tumor type

Coverage considerations are informed by clinical context, evidence strength, and prior therapies:

Gastroenteropancreatic NETs: Use supported by randomized controlled trial evidence (e.g., NETTER‑1) showing improved overall response rate, progression‑free survival, and overall survival compared with long‑acting octreotide; retrospective and registry data provide supporting evidence.evidence from RCTs

NETTER‑1 and NETTER‑2 form primary RCT evidence for GEP‑NETs

Bronchopulmonary or Thymus NETs: Evidence consists primarily of retrospective cohorts (ERASMUS), registries, and case series with reported median PFS ~17.6–23 months and median OS ~44.8–59 months; no randomized trials identified — interpret results with caution due to study limitations.somatostatin receptor–positive disease and progression on first‑line somatostatin analogues

FDA noted limitations in ERASMUS data (missing baseline data, high dropout) that limit interpretability.

Pheochromocytoma and Paraganglioma:

Coverage considerations — pheochromocytoma/paraganglioma

Evidence and guideline context for Lu 177 dotatate in pheochromocytoma/paraganglioma:

Evidence basis: Support comes from systematic reviews, meta‑analyses, nonrandomized studies, and registry data; randomized controlled trials comparing Lu 177 dotatate to iobenguane I 131 are lacking.

See Prado‑Wohlwend et al and SEPTRALU registry

Efficacy measures: Pooled objective response rate approximately 26% and disease control rates around 83–85%; registry‑reported median PFS in some cohorts ~30.6 months, with heterogeneous outcomes across studies.

Outcomes derived from nonrandomized data and meta‑analyses

Safety considerations: Monitor for acute radiation‑related adverse events (e.g., lymphopenia, nausea/vomiting, hepatic enzyme elevations) and long‑term risks (myelodysplastic syndrome, renal failure, leukemia).

Safety monitoring advised per policy

Per the policy, Lutetium Lu 177 dotatate is considered investigational for uses that exceed the FDA-approved total dosing course, for pediatric patients aged ≤17 years, and for any indication not explicitly listed as medically necessary. Specifically, use of the agent at a cumulative total of more than 4 doses or in patients younger than 12 years through 17 years is excluded and may be denied as investigational when the listed medically necessary criteria are not met. These limits align with the FDA‑approved regimen and the policy's investigational statement.

The evidence for Lutetium Lu 177 dotatate in pheochromocytoma and paraganglioma is limited and derived primarily from systematic reviews, single‑arm studies, registries (for example SEPTRALU), and case series rather than randomized controlled trials. The policy notes that before approval of iobenguane I 131, Lu 177 dotatate was used off‑label in this population; available studies report heterogeneous outcomes and do not stratify results by iobenguane (MIBG) uptake status in all cohorts. Guidelines (NCCN) give a category 2A recommendation but emphasize limited data and encourage clinical trial participation for these rare tumor groups.

Many of the nonrandomized data sources are retrospective single‑arm cohorts or registries. The policy emphasizes that such designs, by themselves, are limited evidence for efficacy when there is insufficient documentation tying treated patients to trial‑like eligibility criteria (for example, absence of documented somatostatin receptor positivity, inadequate performance status, or renal function). Single‑arm or registry reports without comparator groups and without trial‑style inclusion/exclusion documentation may therefore be insufficient to support coverage absent additional supporting clinical information.

For bronchopulmonary and thymus neuroendocrine tumors the primary evidence comes from the ERASMUS cohort and retrospective case series. The FDA review identified important limitations: small subgroup sample sizes (e.g., 23 bronchopulmonary and 2 thymus patients in ERASMUS), missing baseline tumor assessments, high dropout rates, and open‑label single‑arm design. These methodological shortcomings limit interpretability of time‑to‑event outcomes (PFS, OS) and therefore constrain the strength of coverage determinations based solely on these data.

No prospective randomized trials directly comparing Lutetium Lu 177 dotatate with iobenguane I 131 in non‑MIBG‑avid pheochromocytoma/paraganglioma were identified. Comparative evidence is therefore lacking, and reported series sometimes include mixed or unstratified iobenguane uptake results. This gap is relevant when considering alternative therapies for MIBG‑avid disease and underscores the need to confirm somatostatin receptor positivity and consider guideline recommendations (including use of iobenguane I 131 for MIBG‑positive patients).

The provided document segment does not contain additional explicit exclusion statements beyond those summarized elsewhere in the policy window. For the full list of exclusions and any additional not‑medically‑necessary statements, reviewers should consult the complete policy text outside this excerpt.

The policy explicitly states that any use that does not meet the listed medically necessary criteria, or that exceeds the approved dosing limits, is considered investigational and not medically necessary. In practice this includes treatments beyond the total of 4 doses specified in the FDA regimen and any indications not enumerated in the medically necessary section; prior authorization and documentation consistent with the policy are required to avoid denial.

There are no data in this segment to support a mandated therapeutic sequence beyond the approved agents. The policy notes that no specific sequence of second‑line therapies is supported by evidence, and that established FDA‑approved agents (for example, streptozocin, everolimus, sunitinib for pancreatic NETs) exist; clinicians should exercise caution when using Lu 177 dotatate outside labeled indications or prior progression on indicated first‑line therapies, and document the clinical rationale.

Use of Lu 177 dotatate for tumors that are not demonstrably somatostatin receptor–positive (for example non‑GEP histologies without evidence of SSTR expression) is unsupported by the available evidence cited in this policy segment. The policy specifically flags use in non‑SSTR‑positive tumors or non‑GEP neuroendocrine histologies without documentation of receptor expression as lacking supportive data and therefore not medically necessary.

The policy requires documented somatostatin receptor expression on appropriate imaging (preferably SSTR‑PET or, if not available, octreotide SPECT) with lesion uptake greater than liver to establish suitability for Lu 177 dotatate. Use of the therapy without such documentation of receptor expression or without supportive imaging evidence is not supported by the studies reviewed and may be considered investigational or may trigger requests for additional documentation.

Within the excerpt provided, explicit statements labeled 'not medically necessary' are limited. The document segment does reiterate that uses not meeting the medically necessary criteria or exceeding dosing thresholds are investigational, but for the full set of specific 'not medically necessary' language and comprehensive exclusions, reviewers should refer to the complete policy outside this window.

Coding and Dosing Information

See codes tablemixed

No codes listed

See Codes tablemixed

No codes listed

Intervention dosing (trial/registry)mixed

7.4 GBq (200 mCi)

Lu 177 dotatate administered per dose as reported in trials/registries

Radiopharmaceutical HCPCS CodesHCPCSCovered

A9513

Lutetium Lu 177, Dotatate, therapeutic 1 millicurie (Lutathera).

CPT / Othermixed

No code(s)

CPT codes not specified in this segment; provider should use appropriate CPT/other billing codes as applicable.

FDA dosing schedule — Lutetium Lu 177 dotatate

FDA dosing schedule7.4 GBq (200 mCi) every 8 weeks for a total of 4 doses; total doses should not exceed 4

Dose timing flexibility8‑week interval may be extended for adverse reactions (eg, thrombocytopenia, anemia, renal or hepatic toxicity)

Per‑dose activity7.4 GBq (200 mCi) administered per treatment as described in prescribing regimen

Creatinine clearance (Cockcroft‑Gault) — discontinuation threshold

Permanent discontinuation threshold (renal)Creatinine clearance < 40 mL/min calculated by Cockcroft‑Gault using actual body weight (permanent discontinuation)

Prior Authorization, Documentation, and Operational Requirements

Prior Authorization

Prior Authorization Required

Prior approval is required. Authorization is limited to FDA‑approved indications for Lutathera® (Lutetium Lu 177 Dotatate) — primarily somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP‑NETs) in adults and the FDA‑approved pediatric expansion for ages ≥12 years. Prior authorization will be for the planned treatment course consistent with the FDA‑approved regimen (7.4 GBq [200 mCi] every 8 weeks for a total of 4 doses) and should document the indication and intended dosing schedule.

Authorization tied to labeled SSTR‑positive GEP‑NETs and pediatric expansion for ≥12 years
Planned dosing schedule must follow FDA regimen: 7.4 GBq (200 mCi) every 8 weeks × 4 doses
Prior approval required

Prior Authorization

Prior Authorization Requirements — Clinical Rationale and Prior Therapies

Requests must include documentation that supports the medical necessity and indication for PRRT. Prior authorization must demonstrate tumor type, prior therapies (including progression despite somatostatin analogues or targeted therapy when applicable), and the clinical rationale for choosing Lutathera over alternative therapies or clinical trial enrollment.

Definitions and Intended Populations

Lutetium Lu 177 dotatate is a radiolabeled somatostatin analogue used as peptide receptor radionuclide therapy (PRRT). It binds somatostatin receptors on tumor cells, is internalized, and delivers beta radiation to induce tumor cell damage. Randomized controlled trial evidence supports benefit in treatment‑refractory gastroenteropancreatic neuroendocrine tumors, while evidence for other tumor types (bronchopulmonary, thymus, pheochromocytoma/paraganglioma) is limited and primarily derived from nonrandomized studies, registries, and case series; guideline bodies provide cautious, sometimes category 2A, recommendations for select non‑GEP indications.

Well‑differentiated neuroendocrine tumor grades and Ki‑67

Grade G1 (well‑differentiated)Ki‑67 index < 3%

Grade G2 (well‑differentiated)Ki‑67 index 3–20%

Lung/thymus gradingPulmonary/thymic tumors classified by mitotic rate and necrosis: typical (<2 mitoses/10 HPF, no necrosis) vs atypical (2–10 mitoses/10 HPF and/or necrosis)

SSTR‑positive imaging — preferred modalities and interpretation

Policy Summary

Payerblue cross blue shield - south dakota

PolicyLutathera (Lutetium Lu 177 Dotatate)

Policy CodePolicy 06.01.38

Change TypeNo material change

Effective DateMay 1, 2018

Next Review Date

Key ActionObtain prior authorization and document SSTR-positive imaging, pathology (including Ki-67), and planned FDA-consistent dosing of 7.4 GBq (200 mCi) every 8 weeks for up to 4 doses.

SourceLink

On This Page

Evidence derived from systematic reviews, meta‑analyses, registries, and single‑arm studies; pooled objective response ~26% and disease control rates ~83–85%; no prospective randomized trials directly comparing Lu 177 dotatate to iobenguane I 131 in non‑MIBG‑avid populations were identified.

unresectable or metastatic disease

Consider available comparators (radiation, ablation, chemoembolization, systemic therapies) and guideline statements when selecting patients.

Patient selection per guidelines: Consider Lu 177 dotatate for somatostatin receptor‑positive, unresectable or metastatic pheochromocytoma/paraganglioma (NCCN category 2A) with caution due to limited data; participation in clinical trials is encouraged.

Confirm SSTR positivity and adequate organ function

Alternative renal toxicity criteria40% increase in baseline serum creatinine or 40% decrease in baseline creatinine clearance also triggers permanent discontinuation

Renal function calculation methodUse Cockcroft‑Gault equation with actual body weight for CrCl assessment

Bilirubin — discontinuation threshold

Permanent discontinuation threshold (hepatic)Bilirubinemia greater than 3 times the upper limit of normal (≥3× ULN) mandates permanent discontinuation

Associated hepatotoxicity criteriaHypoalbuminemia <30 g/L with prothrombin ratio <70% also constitutes hepatotoxicity requiring discontinuation

Monitoring implicationMonitor liver enzymes and bilirubin prior to and during therapy to detect grade 3–4 hepatotoxicity

Creatinine clearance — trial inclusion thresholds

NETTER‑1 inclusion CrClCreatinine clearance ≥50 mL/min was required for NETTER‑1 inclusion

NETTER‑2 exclusionNETTER‑2 excluded patients with creatinine clearance <40 mL/min

Trial-based renal expectationsAssess renal function against pivotal trial thresholds when documenting eligibility

Karnofsky Performance Status — trial thresholds

NETTER‑1 performance status thresholdKarnofsky Performance Status ≥60 was required in NETTER‑1

ERASMUS cohort thresholdERASMUS registry used a broader inclusion with Karnofsky ≥50 in some cohorts

Documentation recommendationRecord Karnofsky score to support trial‑consistent eligibility for prior authorization

Document disease progression despite somatostatin analogue therapy or molecularly targeted therapy for GEP‑NETs when relevant
State prior lines of therapy and why alternatives (e.g., everolimus, temozolomide, hepatic‑directed therapies) are inappropriate or exhausted
Clinical rationale if using as primary vs subsequent therapy

Documentation Required

Verify Indication and Somatostatin Receptor Positivity

Verify the indication and SSTR‑positivity prior to authorization. Provide pathology confirming tumor type and differentiation (including Ki‑67 index) and SSTR‑based imaging that demonstrates uptake in measurable lesions greater than liver uptake. Also supply baseline organ function and performance status information consistent with pivotal trials.

Pathology report with Ki‑67 index and tumor differentiation (well‑differentiated, Ki‑67 ≤20% for NETTER‑1 population)
SSTR‑PET (preferred: Ga‑68 dotatate/dotatoc or Cu‑64 dotatate) showing lesion uptake > liver; Octreoscan SPECT/CT acceptable only if PET unavailable
Baseline labs: adequate bone marrow, renal and hepatic function; creatinine clearance criteria per policy and trial inclusion
Performance status (e.g., Karnofsky or ECOG) and any trial‑based inclusion criteria

Billing Rule

Coding and Reporting — Radiopharmaceutical Billing

Use HCPCS A9513 to report Lutetium Lu 177 dotatate (Lutathera) therapeutic radiopharmaceutical (per millicurie). Claims for radiopharmaceutical services are subject to medical policy review and must include the documentation submitted for prior authorization. Missing or incorrect radiopharmaceutical coding or omission of HCPCS A9513 may result in claim denial.

HCPCS A9513: Lutetium Lu 177, Dotatate, therapeutic 1 millicurie (Lutathera)
Ensure radiopharmaceutical billing aligns with submitted prior authorization documentation and policy requirements
Claims may be reviewed for compliance with dosing limits and course (maximum 4 doses)

Denial Risk

Investigational Uses and Denial Triggers

Investigational/unproven uses will be denied. Examples include requests exceeding the FDA‑approved total of 4 doses, use in pediatric patients ≤17 years (except FDA‑approved pediatric indication ≥12 years), any indication that does not meet the stated criteria, or incomplete documentation supporting eligibility.

Denial risk for >4 total doses
Use in pediatric patients ≤17 years (unless meeting the April 2024 FDA approval criteria for ≥12 years) is investigational
Requests missing required eligibility documentation (pathology, SSTR imaging, baseline labs) may be denied

Documentation Required

Trial‑Based Inclusion Considerations

Trial‑based inclusion criteria should be considered when assessing eligibility. Patients who do not meet key NETTER trial inclusion criteria (e.g., required performance status, creatinine clearance thresholds, SSTR expression on all lesions) may be ineligible under this policy. Participation in clinical trials is encouraged for rare tumor groups or settings with limited randomized data.

NETTER‑1/2 inclusion concepts: confirmed SSTR expression on lesions, sufficient performance status, minimum creatinine clearance thresholds
Patients failing to meet pivotal trial criteria (e.g., creatinine clearance limits, performance status) may not qualify
Encourage clinical trial enrollment for rare indications (pancreatic NETs, pheochromocytoma/paraganglioma, bronchopulmonary/thymic NETs)

Note

Limitations of Single‑Arm ERASMUS Data

Limitations of single‑arm ERASMUS data should inform authorization decisions for bronchopulmonary or thymic NETs. The FDA identified missing baseline data, high dropout, and open‑label design as reasons time‑to‑event outcomes were less interpretable; these limitations may affect coverage determinations for indications lacking randomized evidence.

ERASMUS cohort: retrospective data with missing baseline information and high dropout limiting interpretability
FDA noted caution using single‑arm ERASMUS results to infer efficacy for bronchopulmonary/thymic NETs
Use of Lutathera in these tumor types should be supported by additional documentation given limited RCT evidence

Documentation Required

Required Clinical Documentation for Authorization

Required clinical documentation to support prior authorization includes: pathology confirmation with Ki‑67, SSTR‑based imaging demonstrating uptake > liver, baseline laboratory studies (bone marrow indices, renal function/creatinine clearance, hepatic panel), prior treatment history with dates and responses, performance status, and treating clinician’s rationale including planned dosing schedule and safety monitoring plan.

Pathology report with Ki‑67 index and tumor differentiation (well‑differentiated)
SSTR‑PET report (or Octreoscan SPECT/CT if PET unavailable) showing lesion uptake greater than liver
Baseline labs: CBC with differential, creatinine/creatinine clearance (Cockcroft‑Gault), hepatic panel, and any other organ function tests
Documentation of prior therapies and evidence of progression on first‑line somatostatin analogues when applicable
Planned Lutathera dosing schedule (dates) and documentation of intent to adhere to FDA regimen (maximum 4 doses)
Statement of clinician qualifications to administer radiopharmaceuticals and informed consent documentation

Step Therapy

Place in Therapy and Treatment Sequence

Position Lutathera appropriately in the treatment sequence. For SSTR‑positive inoperable locally advanced or metastatic GEP‑NETs, PRRT is generally considered after progression on first‑line somatostatin analogues; alternative second‑line options should be documented when applicable. For certain situations (per NCCN) Lutathera may be considered earlier (e.g., selected pancreatic or midgut NETs with Ki‑67 ≥10%), but the prior authorization must reflect the stated indication and supporting evidence.

Consider PRRT after progression on first‑line somatostatin analogues (octreotide/lanreotide) for inoperable locally advanced or metastatic GEP‑NETs
Document alternatives and rationale if Lutathera is chosen over second‑line comparators (chemotherapy, everolimus, hepatic‑directed therapy)
If used as first‑line in specific high‑risk presentations (per NCCN), provide documentation supporting that decision

Note

Prior Treatment Considerations and Comparator Therapies

Prior treatment considerations and comparator therapies must be documented. List prior or considered systemic and locoregional therapies (e.g., everolimus, temozolomide, capecitabine/temozolomide, hepatic embolization, external beam radiation) and note if iobenguane I‑131 was considered for MIBG‑positive pheochromocytoma/paraganglioma. Clinical trial participation should be discussed and preferred when appropriate.

Document prior use or consideration of comparator therapies (everolimus, temozolomide, capecitabine, cytotoxic regimens, hepatic‑directed therapies)
Consider iobenguane I‑131 for MIBG‑positive pheochromocytoma/paraganglioma as an alternative
Encourage and document discussion of clinical trial options for rare indications

Preferred modalitiesSSTR‑PET/CT or SSTR‑PET/MRI (eg, Ga‑68 dotatate, Ga‑68 dotatoc, Cu‑64 dotatate)

Acceptable alternativeOctreotide SPECT/CT may be used only if SSTR‑PET is not available (less sensitive)

Uptake interpretationSSTR‑positive status confirmed when uptake in measurable lesions is greater than liver

Lutetium 177 dotatate (Lu 177 dotatate) — definition and mechanism

Agent definitionLutetium 177 dotatate is a radiolabeled somatostatin analogue used for peptide receptor radionuclide therapy (PRRT)

Mechanism of actionBinds somatostatin receptor‑expressing tumor cells, is internalized, and delivers beta radiation from Lu‑177 causing cellular damage via free radical formation

Therapeutic classPeptide receptor radionuclide therapy (radiopharmaceutical) for SSTR‑positive neuroendocrine tumors

GEP‑NETs — definition and functional status

DefinitionGastroenteropancreatic neuroendocrine tumors (GEP‑NETs) are NETs originating in the gastrointestinal tract or pancreas

Functional statusGEP‑NETs may be functional (hormone‑secreting) or nonfunctional; functional tumors can cause syndromes such as carcinoid syndrome

Epidemiology noteApproximately 61% of NETs originate in the GI system or pancreas and are classified as GEP‑NETs

Somatostatin receptor–positive — imaging‑based definition

SSTR‑positive definition (imaging)Tumor lesions demonstrating uptake on somatostatin receptor imaging greater than liver confirm somatostatin receptor–positive status

Implication for therapySSTR‑positive imaging is required to indicate suitability for Lu‑177 dotatate targeting

Accepted tracersGa‑68 dotatate/dotatoc and Cu‑64 dotatate are appropriate PET tracers for assessing SSTR positivity

Ki‑67 index — marker and trial thresholds

Ki‑67 as proliferation markerKi‑67 index is used to grade neuroendocrine tumors and inform eligibility; NETTER‑1 used ≤20% as a threshold

Higher‑grade inclusionNETTER‑2 included tumors with Ki‑67 up to 55% for selected higher‑grade cohorts

Clinical useReport Ki‑67 on pathology to support trial‑consistent eligibility and treatment decisions

Intended population — bronchopulmonary/thymus NETs

Intended bronchopulmonary/thymus populationPatients with locally advanced or metastatic SSTR‑positive bronchopulmonary or thymic NETs who have progressed on first‑line somatostatin analogues

Tumor examplesIncludes typical and atypical pulmonary carcinoids and thymic NETs where SSTR positivity and progression are documented

Evidence contextEvidence derives mainly from retrospective cohorts and registries (eg, ERASMUS) with limitations noted by FDA

Intended population — pheochromocytoma/paraganglioma

Intended pheochromocytoma/paraganglioma populationIndividuals with unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma

Use contextConsidered as an alternative therapy option where SSTR positivity is documented; evidence from nonrandomized studies and registries

Guideline noteNCCN provides a category 2A recommendation for consideration in SSTR‑positive unresectable/metastatic disease

Acute adverse events — short‑term effects requiring monitoring

Common acute events to monitorLymphopenia, nausea/vomiting, increased AST/ALT, hyperglycemia, hypokalemia — monitor during and shortly after treatment

Timing of acute eventsAcute radiation‑related adverse events typically occur in the short‑term post‑treatment period

Documentation recommendationRecord acute adverse events and manage supportively; include in safety monitoring during prior authorization review

Chronic toxicities — long‑term risks after PRRT

Long‑term risksMyelodysplastic syndrome, renal failure, and leukemia are chronic toxicities requiring long‑term monitoring after PRRT

Monitoring implicationInclude baseline and periodic bone marrow, renal, and hepatic function assessment to detect chronic toxicities

Risk attributionChronic hematologic and renal events have been reported in long‑term safety analyses of Lu‑177 dotatate

Lutathera (lutetium Lu 177 dotatate) — agent definition and indication overview

Agent name and classLutathera (lutetium Lu 177 dotatate) — a radiolabeled somatostatin analogue used for peptide receptor radionuclide therapy

Indication overviewUsed to treat somatostatin receptor‑positive neuroendocrine tumors (eg, GEP‑NETs); FDA approval includes adult and pediatric (≥12 years) indications per recent updates

Mechanistic summaryBinds SSTR‑expressing cells, internalizes, and delivers beta emission causing tumor cell damage